About the Event
Rockwell Medical is a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management. The company recently submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for home infusion therapy.
Their IND application with the FDA was submitted in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate, designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting. This increases access to treatment helping the company improve outcomes for patients around the world.
Join our webinar as Dr. Russell Ellison, Rockwell Medical President & CEO, shares the company’s latest news and how it’s moving forward to take advantage of the big opportunity in home infusion therapy for anemia.